The FDA has granted orphan drug designation to Iecure Inc.'s lead product candidate GTP-506, an investigational product for the treatment of ornithine transcarbamylase (OTC) deficiency.
Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 (onternabez) as a combination product with Qifenda (favipiravir) 400 mg, a commercial-stage broad-spectrum antiviral drug.
Evaxion Biotech A/S, in collaboration with UMass Chan Medical School, has received a grant from the U.S. National Institutes of Health (NIH) for the development of a lead vaccine candidate for gonorrhea.
Biovaxys Technology Corp. has announced that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the company's vaccine for SARS-CoV, which is being used in the collaboration with The Ohio State University (OSU) to develop a pan-sarbecovirus vaccine.
Tenaya Therapeutics Inc. has received FDA clearance of its IND application to begin clinical testing of TN-301, a highly selective small-molecule inhibitor of histone deacetylase 6 (HDAC6) initially being developed for heart failure with preserved ejection fraction (HFpEF).
Investigators described preclinical data for AZD-5462 (Astrazeneca plc/Mitsubishi Tanabe Pharma Corp.), a novel oral agonist of the relaxin family peptide receptor 1 (RXFP1), being developed for the treatment of cardiorenal disease.
Nanotics LLC has established a research collaboration with Mass General Cancer Center (MGCC), a program of Massachusetts General Hospital (MGH), to develop Nanots that target the soluble forms of tumor necrosis factor (TNF) receptors (sTNF-Rs).
Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd. has synthesized new antibody-drug conjugates (ADC) or antigen binding fragments targeting claudin 18 (CLDN18) and linked to cytotoxic drug reported to be useful for the treatment of cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has presented new Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
RSS
